您的位置: 首页 > 2023年10月 第54卷 第10期 > 文字全文
2023年7月 第38卷 第7期11
目录

羟氯喹联合半量激素与足量激素治疗IgA肾病的比较

Comparison of hydroxychloroquine combined with half-dose glucocorticoid and full-dose glucocorticoid in the treatment of IgA nephropathy

来源期刊: 广州医药 | 39-45 发布时间:2023-11-07 收稿时间:2025/11/13 18:30:00 阅读量:30
作者:
关键词:
羟氯喹糖皮质激素IgA肾病24 h尿蛋白定量肾功能不良反应
hydroxychloroquineglucocorticoidIgA nephropathy24-hour urine proteinrenal functionadverse reaction
DOI:
10.3969/j.issn.1000-8535.2023.10.005
收稿时间:
2023-03-27 
修订日期:
 
接收日期:
 
引用总数:
3  
目的 对比羟氯喹联合半量激素与足量糖皮质激素(激素)治疗IgA肾病在减少尿蛋白、保护肾功能方面的效果以及不良反应的发生率。方法 筛选2020年6月—2022年1月我院收治基线尿蛋白排泄量>1 g/ d、基线估算肾小球滤过率>15 mL/min的IgA肾病患者为研究对象,随机分为羟氯喹+半量激素(Q+G)组及足量激素(G)组。Q+G组予羟氯喹及泼尼松0.5 mg/(kg·d),G组予泼尼松 1 mg/(kg·d),比较2组在治疗2、4、6个月后24 h尿蛋白定量的改变值;比较2组6个月内24 h尿蛋白较基线下降>30%的比例、24 h尿蛋白定量下降至1 g以下的比例、估算肾小球滤过率下降>30%的比例以及不良反应发生率。结果 纳入Q+G组49例,G组46例。2组在治疗2、4、6个月后的24 h尿蛋白定量改变值、6个月内24 h尿蛋白较基线下降>30%的比例、24 h尿蛋白定量下降至1 g以下的比例、6个月内估算肾小球滤过率下降>30%的比例比较差异均无统计学意义(均P>0.05);Q+G组不良反应发生率低于G组(P<0.05)。结论 与足量激素治疗相比,羟氯喹联合半量激素治疗尿蛋白持续>1 g/d的IgA肾病患者在减少尿蛋白、保护肾功能中的效果相近,而不良反应的发生率较低。
Objective Compared with full-dose glucocorticoid,to evaluate the effect of hydroxychloroquine combined with half-dose glucocorticoid in the treatment of IgA nephropathy in reducing urinary protein and protecting renal function,as well as the incidence of adverse reactions. Methods From June 2020 to January 2022,patients with IgA nephropathy whose baseline urinary protein excretion>1 g/d and baseline estimate glomerular filtration rate>15 mL/min were enrolled and randomly divided into hydroxychloroquine combined with half-dose glucocorticoid(Q+G)group and full-dose glucocorticoid(G)group. Each patient in Q+G group was given oral hydroxychloroquine and oral prednisone at a dose of 0. 5 mg/(kg·d). Each patient in G group was given prednisone at a dose of 1 mg/(kg·d). The changes in 24-hour urine protein quantification between the two groups at 2,4 and 6 months of treatment were compared;the proportions of 24-hour urine protein decreased by more than 30%,24-hour urine protein decreased to less than 1 g,estimate glomerular filtration rate decreased >30% and adverse reactions within 6 months were compared between the two groups. Results Fourty-nine cases were enrolled in Q+G group and 46 cases in G group. There was no significant difference in the 24-hour urine protein changes between the two groups at 2,4 and 6 months of treatment. The proportion of 24-hour urine protein decreased by 30%,the proportion of the 24-hour urine protein decreased to below 1 g and the proportions of patients whose estimate glomerular filtration rate decreased by >30% within 6 months between the two groups were not significantly different. The proportion of adverse reactions in Q+G group was lower than that in G group. Conclusions Hydroxychloroquine combined with half-dose glucocorticoid has similar effects in reducing urinary protein and protecting renal function and lowering incidence of adverse reactions compared with full-dose glucocorticoid therapy in the treatment of patients with IgA nephropathy whose urinary protein excretion > 1 g/d.
1、 蔡增苗. 激素联合羟氯喹治疗IgA肾病的效果[J].中国现代药物应用,2022,16(15):112-115. 蔡增苗. 激素联合羟氯喹治疗IgA肾病的效果[J].中国现代药物应用,2022,16(15):112-115.
2、 王超超,林永强,蔡小巧,等.羟氯喹与糖皮质激素治疗IgA肾病效果比较[J].浙江医学,2022,44(5):523-525. 王超超,林永强,蔡小巧,等.羟氯喹与糖皮质激素治疗IgA肾病效果比较[J].浙江医学,2022,44(5):523-525.
3、 YANG Y Z,CHEN P,LIU L J,et al.Comparison of the effects of hydroxychloroquine and corticosteroid treatment on proteinuria in IgA nephropathy:a case-control study[J].BMC Nephrol,2019,20(1):297. YANG Y Z,CHEN P,LIU L J,et al.Comparison of the effects of hydroxychloroquine and corticosteroid treatment on proteinuria in IgA nephropathy:a case-control study[J].BMC Nephrol,2019,20(1):297.
4、 刘密迦,李贵森.羟氯喹联合治疗对IgA肾病残余蛋白尿的影响[J].实用医院临床杂志,2021,18(2):142-145. 刘密迦,李贵森.羟氯喹联合治疗对IgA肾病残余蛋白尿的影响[J].实用医院临床杂志,2021,18(2):142-145.
5、 彭露婷,黄志荣,官慧儿,等.羟氯喹补充治疗IgA肾病安全性和有效性的系统评价[J].中国医院药学杂志,2022,42(14):1463-1468. 彭露婷,黄志荣,官慧儿,等.羟氯喹补充治疗IgA肾病安全性和有效性的系统评价[J].中国医院药学杂志,2022,42(14):1463-1468.
6、 潘怡璇,陈肖蓉,任萍萍,等.羟氯喹治疗IgA肾病疗效与安全性的单中心回顾性分析[J].中华肾脏病杂志,2022,38(2):81-90. 潘怡璇,陈肖蓉,任萍萍,等.羟氯喹治疗IgA肾病疗效与安全性的单中心回顾性分析[J].中华肾脏病杂志,2022,38(2):81-90.
7、 LIU L J,YANG Y Z,SHI S F,et al.Effects of hydroxychloroquine on proteinuria in IgA nephropathy:a randomized controlled trial[J].Am J Kidney Dis,2019,74(1):15-22. LIU L J,YANG Y Z,SHI S F,et al.Effects of hydroxychloroquine on proteinuria in IgA nephropathy:a randomized controlled trial[J].Am J Kidney Dis,2019,74(1):15-22.
8、 李优,姜红,李维.羟氯喹对IgA肾病大鼠肾脏病理和Toll样受体4表达的影响[J].中国医科大学学报,2020,49(11):997-1001. 李优,姜红,李维.羟氯喹对IgA肾病大鼠肾脏病理和Toll样受体4表达的影响[J].中国医科大学学报,2020,49(11):997-1001.
9、 魏凯悦,米焱.羟氯喹治疗IgA肾病的研究进展[J].肾脏病与透析肾移植杂志,2022,31(3):266-270. 魏凯悦,米焱.羟氯喹治疗IgA肾病的研究进展[J].肾脏病与透析肾移植杂志,2022,31(3):266-270.
10、 DURCAN L,PETRI M.Immunomodulators in SLE:Clinical evidence and immunologic actions[J].J Autoimmun,2016(74):73-84. DURCAN L,PETRI M.Immunomodulators in SLE:Clinical evidence and immunologic actions[J].J Autoimmun,2016(74):73-84.
11、 YEO S C,CHEUNG C K,BARRATT J.New insights into the pathogenesis of IgA nephropathy[J].Pediatr Nephrol,2018,33(5):763-777. YEO S C,CHEUNG C K,BARRATT J.New insights into the pathogenesis of IgA nephropathy[J].Pediatr Nephrol,2018,33(5):763-777.
12、 LAI K N.Pathogenesis of IgA nephropathy[J].Nat Rev Nephrol,2012,8(5):275-283. LAI K N.Pathogenesis of IgA nephropathy[J].Nat Rev Nephrol,2012,8(5):275-283.
13、 Kidney Disease:Improving Global Outcomes(KDIGO)Glomerular Diseases Work Group.KDIGO 2021 clinical practice guideline for the management of glomerular diseases[J].Kidney Int,2021,100(4S):S1-S276. Kidney Disease:Improving Global Outcomes(KDIGO)Glomerular Diseases Work Group.KDIGO 2021 clinical practice guideline for the management of glomerular diseases[J].Kidney Int,2021,100(4S):S1-S276.
14、 肖永真,杨晓.羟氯喹在IgA肾病中的应用[J].临床肾脏病杂志,2021,21(3):253-257. 肖永真,杨晓.羟氯喹在IgA肾病中的应用[J].临床肾脏病杂志,2021,21(3):253-257.
15、 LAI K N,TANG S C,SCHENA F P,et al.IgA nephropathy[J].Nat Rev Dis Primers,2016(2):16001. LAI K N,TANG S C,SCHENA F P,et al.IgA nephropathy[J].Nat Rev Dis Primers,2016(2):16001.
1、宋开永.基于黏膜免疫探讨利咽汤对气阴两虚兼风热型IgA肾病的临床研究[D].成都中医药大学,2024.DOI:10.26988/d.cnki.gcdzu.2024.000560. 宋开永.基于黏膜免疫探讨利咽汤对气阴两虚兼风热型IgA肾病的临床研究[D].成都中医药大学,2024.DOI:10.26988/d.cnki.gcdzu.2024.000560.
2、张寒.国医大师邹燕勤教授治疗IgA肾病的用药规律数据挖掘及临床疗效研究[D].南京中医药大学,2025.DOI:10.27253/d.cnki.gnjzu.2025.000644. 张寒.国医大师邹燕勤教授治疗IgA肾病的用药规律数据挖掘及临床疗效研究[D].南京中医药大学,2025.DOI:10.27253/d.cnki.gnjzu.2025.000644.
3、康黔莉.羟氯喹治疗狼疮性肾炎伴周围血管炎的效果研究[J].当代医药论丛,2025,23(11):86-88. 康黔莉.羟氯喹治疗狼疮性肾炎伴周围血管炎的效果研究[J].当代医药论丛,2025,23(11):86-88.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录